S&P 500   3,925.95 (+0.24%)
DOW   32,099.40 (+0.75%)
QQQ   305.05 (-0.10%)
AAPL   155.05 (+0.03%)
MSFT   274.68 (-1.70%)
META   197.79 (+1.11%)
GOOGL   100.66 (-0.94%)
AMZN   97.25 (-1.72%)
TSLA   177.47 (-1.48%)
NVDA   257.70 (+0.17%)
NIO   8.11 (-1.82%)
BABA   79.88 (-2.19%)
AMD   96.24 (-1.64%)
T   18.30 (+0.94%)
F   11.29 (-0.09%)
MU   56.73 (+0.12%)
CGC   1.97 (-1.50%)
GE   90.90 (+0.68%)
DIS   93.75 (+0.59%)
AMC   4.21 (+0.72%)
PFE   40.12 (+0.05%)
PYPL   72.88 (-0.15%)
NFLX   297.05 (-2.13%)
S&P 500   3,925.95 (+0.24%)
DOW   32,099.40 (+0.75%)
QQQ   305.05 (-0.10%)
AAPL   155.05 (+0.03%)
MSFT   274.68 (-1.70%)
META   197.79 (+1.11%)
GOOGL   100.66 (-0.94%)
AMZN   97.25 (-1.72%)
TSLA   177.47 (-1.48%)
NVDA   257.70 (+0.17%)
NIO   8.11 (-1.82%)
BABA   79.88 (-2.19%)
AMD   96.24 (-1.64%)
T   18.30 (+0.94%)
F   11.29 (-0.09%)
MU   56.73 (+0.12%)
CGC   1.97 (-1.50%)
GE   90.90 (+0.68%)
DIS   93.75 (+0.59%)
AMC   4.21 (+0.72%)
PFE   40.12 (+0.05%)
PYPL   72.88 (-0.15%)
NFLX   297.05 (-2.13%)
S&P 500   3,925.95 (+0.24%)
DOW   32,099.40 (+0.75%)
QQQ   305.05 (-0.10%)
AAPL   155.05 (+0.03%)
MSFT   274.68 (-1.70%)
META   197.79 (+1.11%)
GOOGL   100.66 (-0.94%)
AMZN   97.25 (-1.72%)
TSLA   177.47 (-1.48%)
NVDA   257.70 (+0.17%)
NIO   8.11 (-1.82%)
BABA   79.88 (-2.19%)
AMD   96.24 (-1.64%)
T   18.30 (+0.94%)
F   11.29 (-0.09%)
MU   56.73 (+0.12%)
CGC   1.97 (-1.50%)
GE   90.90 (+0.68%)
DIS   93.75 (+0.59%)
AMC   4.21 (+0.72%)
PFE   40.12 (+0.05%)
PYPL   72.88 (-0.15%)
NFLX   297.05 (-2.13%)
S&P 500   3,925.95 (+0.24%)
DOW   32,099.40 (+0.75%)
QQQ   305.05 (-0.10%)
AAPL   155.05 (+0.03%)
MSFT   274.68 (-1.70%)
META   197.79 (+1.11%)
GOOGL   100.66 (-0.94%)
AMZN   97.25 (-1.72%)
TSLA   177.47 (-1.48%)
NVDA   257.70 (+0.17%)
NIO   8.11 (-1.82%)
BABA   79.88 (-2.19%)
AMD   96.24 (-1.64%)
T   18.30 (+0.94%)
F   11.29 (-0.09%)
MU   56.73 (+0.12%)
CGC   1.97 (-1.50%)
GE   90.90 (+0.68%)
DIS   93.75 (+0.59%)
AMC   4.21 (+0.72%)
PFE   40.12 (+0.05%)
PYPL   72.88 (-0.15%)
NFLX   297.05 (-2.13%)
NASDAQ:AIKI

AIkido Pharma - AIKI Stock Forecast, Price & News

$3.50
+0.01 (+0.29%)
(As of 03/17/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.43
$3.64
50-Day Range
$3.49
$4.45
52-Week Range
$3.31
$11.48
Volume
24,430 shs
Average Volume
79,326 shs
Market Capitalization
$19.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

AIkido Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
349.4% Upside
$16.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.70) to ($1.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

726th out of 983 stocks

Commercial Physical Research Industry

13th out of 16 stocks


AIKI stock logo

About AIkido Pharma (NASDAQ:AIKI) Stock

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Stock News Headlines

Dominari Holdings Provides Business Update
Big Potential, Tiny Penny Stock
Little-known stock ready to disrupt the $4.37 trillion wellness market
AIkido Share Repurchase Continues
AIkido Purchases More Shares
Big Potential, Tiny Penny Stock
Little-known stock ready to disrupt the $4.37 trillion wellness market
Share Repurchase Program Continues
AIkido Pharma Continues Share Repurchase Program
AIkido Pharma Provides Update on Share Repurchase Program
AIkido Pharma Confirms Receipt of Unsolicited Offer
Aikido Pharma Inc
AIkido Pharma regains Nasdaq compliance
AIkido Pharma Inc. Appoints New Director, Soo Yu
Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
See More Headlines
Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Company Calendar

Today
3/20/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AIKI
Employees
4
Year Founded
1967

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+349.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$19.27 per share

Miscellaneous

Free Float
5,013,000
Market Cap
$19.53 million
Optionable
Not Optionable
Beta
0.93

Social Links


Key Executives

  • Mr. Anthony C. Hayes Esq. (Age 54)
    CEO, Principal Financial Officer, Principal Accounting Officer & Director
    Comp: $960k
  • Mr. Darrell Dotson
    VP of Drug Devel. & Gen. Counsel
  • Mr. Carlos Aldavero
    Pres of Dominari Financial













AIKI Stock - Frequently Asked Questions

Should I buy or sell AIkido Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AIkido Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AIKI shares.
View AIKI analyst ratings
or view top-rated stocks.

What is AIkido Pharma's stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year price objectives for AIkido Pharma's stock. Their AIKI share price forecasts range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 349.4% from the stock's current price.
View analysts price targets for AIKI
or view top-rated stocks among Wall Street analysts.

How have AIKI shares performed in 2023?

AIkido Pharma's stock was trading at $3.28 on January 1st, 2023. Since then, AIKI stock has increased by 8.5% and is now trading at $3.56.
View the best growth stocks for 2023 here
.

When is AIkido Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our AIKI earnings forecast
.

When did AIkido Pharma's stock split?

AIkido Pharma shares reverse split on Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of AIkido Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIkido Pharma investors own include Biocept (BIOC), AIM ImmunoTech (AIM), Nuwellis (CHFS), Foresight Autonomous (FRSX), iBio (IBIO), Exela Technologies (XELA), Bionano Genomics (BNGO), Check-Cap (CHEK), Digital Ally (DGLY) and Purple Biotech (KTOV).

What is AIkido Pharma's stock symbol?

AIkido Pharma trades on the NASDAQ under the ticker symbol "AIKI."

How do I buy shares of AIkido Pharma?

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AIkido Pharma's stock price today?

One share of AIKI stock can currently be purchased for approximately $3.56.

How much money does AIkido Pharma make?

AIkido Pharma (NASDAQ:AIKI) has a market capitalization of $19.53 million and generates $10,000.00 in revenue each year. The business services provider earns $-7,170,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.

Does AIkido Pharma have any subsidiaries?
The following companies are subsidiares of AIkido Pharma: Hoth Therapeutics.
Read More
How can I contact AIkido Pharma?

AIkido Pharma's mailing address is ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020. The official website for the company is www.spherix.com. The business services provider can be reached via phone at (112) 745-1374, via email at investorrelations@spherix.com, or via fax at 703-992-9348.

This page (NASDAQ:AIKI) was last updated on 3/20/2023 by MarketBeat.com Staff